We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
The COVID-19 pandemic has proven a major disruption to the clinical trials industry, forcing the delay of many planned studies and driving drug sponsors and researchers to adapt their study methods so that trials can continue. But many adaptations being used to allow trials to move forward ultimately could yield a more nimble industry that can quickly and effectively respond to clinical trial disruptions. Read More
